{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/","result":{"pageContext":{"chapter":{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care","depth":2,"htmlHeader":"<!-- begin field 5d14aadf-5a44-475c-ae40-7a40c5751bf5 --><h2>Scenario: Follow up of confirmed dementia in primary care</h2><!-- end field 5d14aadf-5a44-475c-ae40-7a40c5751bf5 -->","summary":"Covers the ongoing care and support of people with dementia and their family/carers in primary care, management of challenging behaviour related to dementia and when to seek advice or refer a person with dementia.","htmlStringContent":"<!-- begin item d661e56d-b801-4d4c-8b75-ae17d81f69af --><!-- begin field 1c0a5962-dcd6-4c58-bccf-acbd0086d9a7 --><p>From age 30 years onwards.</p><!-- end field 1c0a5962-dcd6-4c58-bccf-acbd0086d9a7 --><!-- end item d661e56d-b801-4d4c-8b75-ae17d81f69af -->","topic":{"id":"de9cbb4d-2d69-500f-be27-dc83f76dc3ba","topicId":"2491e3e7-cc21-42b9-8972-e54804b4782f","topicName":"Dementia","slug":"dementia","lastRevised":"Last revised in October 2020","chapters":[{"id":"af834011-0042-530a-8f9a-acd5828e0a34","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0360b83-4555-5079-897f-12b2d555c1af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes"},{"id":"7ced1224-30c2-5f30-9caf-3764f3665ae4","slug":"update","fullItemName":"Update"}]},{"id":"fae05cff-ad98-52fa-89b4-b97369195d59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2f3b4bd3-e7cf-5492-afe0-0a5b230eab7e","slug":"goals","fullItemName":"Goals"},{"id":"9104785e-e491-5ca3-b3d3-7e951385bce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a9c56eb4-bc0e-51cc-b486-a54c23906bc0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebf62eba-a4cd-536c-8c9f-c9505b0e7482","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a71b8dc2-79f8-5d24-b668-c792abc5a624","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c87232ba-6926-5ff2-98d2-f8839b0c0d37","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46c6316f-eec0-580a-80ec-2112d2f0122f","slug":"definition","fullItemName":"Definition"},{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes"},{"id":"87101d89-6073-57cc-b247-48be586ef185","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"58f6ec5a-c90b-5e64-a476-fc9fca39c6ae","slug":"prevalence","fullItemName":"Prevalence"},{"id":"994469e3-f824-5f48-b755-7f74dd360680","slug":"prognosis","fullItemName":"Prognosis"},{"id":"718f9ed4-d725-5f6e-a86f-5df88719cd52","slug":"complications","fullItemName":"Complications"}]},{"id":"366bcbe3-827a-5e08-9d81-8de84e46fefd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"565bac2a-ada3-5b0a-ab7d-6681501b2c4a","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"4c0fe55f-40c9-5a1c-8cf3-1ec8d88406d5","slug":"assessment","fullItemName":"Assessment"},{"id":"ef7780bd-8e94-5f95-870f-92ab930c4365","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","fullItemName":"Management","slug":"management","subChapters":[{"id":"c6c0cbc2-18fc-5bf8-973d-bc38b9001f28","slug":"suspected-dementia","fullItemName":"Scenario: Suspected dementia"},{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care"},{"id":"343a59fa-439e-5ab9-9d3b-28a893d55d2f","slug":"management-of-end-stage-dementia","fullItemName":"Scenario: Management of end-stage dementia"}]},{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors"},{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride"}]},{"id":"1e87c908-2ab5-5cba-8d6a-958c03f7a6cd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fc7a2bcf-854b-5ca4-9b02-2dcaaebe1162","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7bcb26a3-cc69-5201-9fd9-6353e27b412f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c383917-58d0-5036-8217-5d9fd81cb2cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fdb8af52-aeee-52bd-be79-c5534939d42f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a9f930f3-f8b6-5c8f-b8ca-b3155e0c23d3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"668c11fa-1873-58d4-b0e2-3eab90e8fbff","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67c4aef9-fbf4-5bf6-8dc5-c501f74b1fe3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0ead0a69-0d9b-52fa-811d-561071fb6374","slug":"follow-up-in-primary-care","fullItemName":"Follow up in primary care","depth":3,"htmlHeader":"<!-- begin field 1facea5b-9cc1-408f-bbb8-0a1ffff83fb2 --><h3>How should I follow up a person who has been diagnosed with dementia?</h3><!-- end field 1facea5b-9cc1-408f-bbb8-0a1ffff83fb2 -->","summary":null,"htmlStringContent":"<!-- begin item ba6112ca-9974-44d4-9a67-373c428b169f --><!-- begin field f396e64b-156c-41da-b47e-95d41729bf07 --><p><strong>Following a diagnosis of dementia:</strong></p><ul><li><strong>Discuss the diagnosis and give written information to the person and their family/carer.</strong> <ul><li>Explain the symptoms, treatment, and prognosis of dementia to the person and, if the person consents, their carer/family.</li><li>Give written information on local <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/#support-information\">dementia support services</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/#support-information\">sources of information</a>, for example voluntary support organizations, advocacy services, and sources of financial and legal advice.</li></ul></li><li><strong>Identify the persons wishes for future care (advance care planning) while the person still has mental capacity.</strong> This should include discussion on:<ul><li>Advance statements — what the person wishes to be done if they lose capacity or the ability to communicate (not legally binding).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/dementia/diagnosis/assessment/#mental-capacity-act-2005\">Advance decisions</a> to refuse treatment in a predefined future situation (sometimes called 'living wills’).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/dementia/diagnosis/assessment/#mental-capacity-act-2005\">Lasting power of attorney</a> — documentation on who the person wants to make decisions (for example on personal health and welfare) when they are no longer able to.</li><li>Preferred place of care — decisions on future care and the place where the person would prefer to die.</li></ul></li><li><strong>Monitor physical and mental health and functional ability</strong><ul><li>Be alert for co-morbidities such as depression and/or anxiety. For further information see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li><li>Exclude delirium if an abrupt deterioration in cognitive function is noted — cognitive impairment is a risk factor for delirium. For further information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/delirium/\">Delirium</a>.</li><li>Consider the need for referral to other services such as social services, occupational therapy, physiotherapy, and speech and language therapy. </li><li>Discuss driving — the person is legally required to inform the Driver and Vehicle Licensing Agency (DVLA) when dementia is diagnosed.<ul><li>Factsheets on driving (for example, from the <a data-hyperlink-id=\"6b5128ac-1426-46aa-857a-a8f7014a6c75\" href=\"https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=144\">Alzheimer’s Society</a> website) are available and can be used to help people with dementia decide when to give up driving. All drivers with dementia must eventually stop driving when dementia becomes moderately severe, and in many cases earlier.</li><li>Where there is uncertainty over the person's driving ability, a driving assessment can be undertaken at one of the DVLA assessment centres. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/suspected-dementia/#driving\">Driving</a> for more information.</li></ul></li></ul></li><li><strong>Monitor response to, and adverse effects from, dementia treatments and the progression of dementia</strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/#specialist-treatment\">Non-pharmacological interventions</a> for cognitive symptoms and maintaining function (such as structured group cognitive stimulation programmes) should be offered by specialist services for people with mild to moderate dementia. </li><li><a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/#specialist-treatment\">Pharmacological interventions</a> for the cognitive symptoms of dementia may be prescribed under a shared-care agreement with secondary care. Prescribing and monitoring instructions for primary care should be provided by secondary care — seek advice from the initiating specialist if unsure.<ul><li>Dosette boxes or memory aids for medication may be needed.</li><li>Aetylcholinesterase inhibitors can cause fatigue, dizziness, and muscle cramps, mainly when initiating or increasing the dose — assess the person's ability to drive routinely. For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/prescribing-information/\">Prescribing</a>.</li></ul></li><li>Use a validated <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/diagnosis/assessment/#cognitive-assessment-tools\">cognitive assessment tool</a> to monitor decline in cognition.</li></ul></li><li><strong>Ask about <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/diagnosis/clinical-features/\">behavioural and psychological symptoms of dementia</a> (BPSD):</strong><ul><li>If BPSD are reported, assess for and treat reversible causes where possible.</li><li>Symptoms may resolve spontaneously.within a short time. If they do not, consider non-pharmacological interventions (depending on local availability) such as:<ul><li>Aromatherapy.</li><li>Multisensory stimulation.</li><li>Exercise.</li><li>Therapeutic use of music and/or dancing.</li><li>Animal-assisted therapy.</li><li>Massage.</li></ul></li><li>Antipsychotic drugs (such as haloperidol) should be avoided, if possible, in the management of BPSD — if prescribed, this should only be by a specialist (such as an elderly care psychiatrist or physician). </li><li>If challenging behaviour requires urgent treatment (when the person is a danger to themselves or others) and underlying causes (such as discomfort, thirst, or the need for the toilet) have been addressed:<ul><li>Advise moving the person to a safe, low-stimulation environment (such as a quiet room) away from others.</li><li>Advise use of verbal and non-verbal de-escalation techniques (such as active listening, effective verbal responding, pictures, and symbols). For more information on de-escalation techniques, see the National Institute for Health and Care Excellence (NICE) Pathway on <a data-hyperlink-id=\"5dc79fd6-3294-4c9f-8fcb-a8f7014a6e08\" href=\"http://pathways.nice.org.uk/pathways/violence-and-aggression\">Violence and aggression</a>.</li><li>If these measures fail, seek advice from an elderly care psychiatrist, the challenging behaviour team (if available locally), or an elderly care physician. Depending on the specific situation, short-term (off-label) use of drugs for behavioural control (such as haloperidol or lorazepam) may be suggested. For further information, see the <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/prescribing-information/\">Prescribing information</a> sections for lorazepam and haloperidol.</li></ul></li><li><strong>Monitor the mental and physical health of the caregiver.</strong><ul><li>Ask about sources of support (formal and informal), financial difficulties, what they would like help with, their physical and mental health and the positive aspects of caring.</li><li>Offer referral for psychological therapy (including cognitive behavioural therapy) and training in stress reduction and communication and problem solving, if appropriate.</li><li>Signpost to <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/#support-information\">sources of information and support</a>.</li></ul></li><li><strong>Ensure the person with dementia has a care manager and a regularly reviewed care plan.</strong><ul><li>Care plans for people with dementia should include details on diagnosis and treatment (non-pharmacological and pharmacological methods), environmental modifications, sources of information (such as where to find local support groups), and review plans.</li></ul></li><li><strong>Make clear follow-up arrangements.</strong></li><li><strong>Refer or seek advice from a specialist (such as an elderly care psychiatrist, challenging behaviour team, or elderly care physician) if:</strong><ul><li>The person has comorbid emotional disorders such as depression and/or anxiety.</li><li>BPSD develop which do not respond to initial non-pharmacological management or if the person is a risk to themselves or others.</li><li>Detention under the Mental Health Act (1983) is being considered. For further information, see the section on the Mental Health Act (1983) in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/self-harm/\">Self-harm</a>.</li><li>A dose change of dementia drugs may be needed, an interacting drug is being considered, or the person has adverse effects from dementia drugs.</li></ul></li></ul></li></ul><!-- end field f396e64b-156c-41da-b47e-95d41729bf07 --><!-- end item ba6112ca-9974-44d4-9a67-373c428b169f -->","subChapters":[{"id":"44b9eeba-576b-5f9a-a451-a1a287b11dcd","slug":"support-information","fullItemName":"Support and information","depth":4,"htmlHeader":"<!-- begin field 5c512100-9d09-4bf6-8cf6-bf90fe100f67 --><h4>Sources of support and information for people with dementia and their family/carers.</h4><!-- end field 5c512100-9d09-4bf6-8cf6-bf90fe100f67 -->","summary":null,"htmlStringContent":"<!-- begin item 43a44e58-0265-486f-93b1-a0751543597d --><!-- begin field 7280f768-f7b8-445d-86de-ac6aacd0fd87 --><ul><li><strong>Sources of support and information for people with dementia and their family/carers, include:</strong><ul><li>The National Institute for Health and Care Excellence (NICE) — information for the public on dementia (<a data-hyperlink-id=\"4a498a72-3f24-4fea-bef1-a8f701522a75\" href=\"http://www.nice.org.uk/guidance/cg42/ifp/chapter/About-this-information\">www.nice.org.uk/guidance/cg42/ifp/chapter/About-this-information</a>).</li><li>The Royal College of Psychiatrists — a fact sheet on dementia (<a data-hyperlink-id=\"9d6c1447-f89d-4cfd-be24-a8f701522a7e\" href=\"http://www.rcpsych.ac.uk/healthadvice/problemsdisorders/dementiakeyfacts.aspx\">www.rcpsych.ac.uk/healthadvice/problemsdisorders/dementiakeyfacts.aspx</a>).</li><li>NHS A-Z — a patient information article on dementia (<a data-hyperlink-id=\"525ba411-41e3-4786-a8ca-a8f701522c20\" href=\"http://www.nhs.uk/conditions/dementia\">www.nhs.uk/conditions/dementia</a>). </li><li>The Alzheimer's Society — information on all types of dementia (<a data-hyperlink-id=\"b615af16-6b36-4bc4-bb5b-a8f701522c41\" href=\"http://www.alzheimers.org.uk/\">www.alzheimers.org.uk</a>). <ul><li>A leaflet '<a data-hyperlink-id=\"abc875e3-e932-45e5-9d4e-a8f701522c6a\" href=\"https://www.alzheimers.org.uk/thisisme\">This is me</a>' can be printed to help support people with dementia in unfamiliar place or with unfamiliar carers.</li></ul></li><li>Alzheimer’s Research UK, which provides health information relating to dementia (<a data-hyperlink-id=\"03f744ed-4a3f-4ece-8622-a8f701522c88\" href=\"http://www.alzheimersresearchuk.org/\">www.alzheimersresearchuk.org</a>).</li><li>The Lewy Body Society, which provides information and support for families/carers affected by Lewy Body dementia (<a data-hyperlink-id=\"4b092857-108b-4e8e-8898-a8f701522cf2\" href=\"http://www.lewybody.org/\">www.lewybody.org</a>).</li><li>The Frontotemporal Dementia Support Group (formerly Pick's Disease Support Group), which provides information and support for people with frontotemporal dementia and their family/carers (<a data-hyperlink-id=\"4fe36017-0def-45b7-9895-a8f701522dfd\" href=\"http://www.ucl.ac.uk/drc/support-groups/FTD-support-group\">www.ucl.ac.uk/drc/support-groups/FTD-support-group</a>).</li><li>Carers UK, which provides help for people caring for a sick, disabled, or elderly person at home (<a data-hyperlink-id=\"b5175520-94a7-48fa-a598-a8f701522eff\" href=\"http://www.carersuk.org/\">www.carersuk.org</a>).</li><li>Dementia pathfinders, which provides education for people working in the dementia care field, and care and support for people with dementia and their family/carers (<a data-hyperlink-id=\"1201e126-8d0c-4e14-9634-a8f701522f9e\" href=\"http://www.dementiapathfinders.org/\">www.</a><a data-hyperlink-id=\"b5dea7c0-7ad0-4c2e-920f-a8f701522fa8\" href=\"http://www.dementiapathfinders.org/\">dementiapathfinders.org</a>).</li><li>The Office of the Public Guardian, which supports decision making (within the framework of the Mental Capacity Act 2005) for people who lack capacity or would like to plan for their future (<a data-hyperlink-id=\"25ed815d-3da7-473d-8e9a-a8f701522fa8\" href=\"http://www.publicguardian.gov.uk/\">www.publicguardian.gov.uk</a>).</li></ul></li></ul><!-- end field 7280f768-f7b8-445d-86de-ac6aacd0fd87 --><!-- end item 43a44e58-0265-486f-93b1-a0751543597d -->","subChapters":[]},{"id":"1804fbb3-c764-5c29-85c8-c3e93bc9143e","slug":"specialist-treatment","fullItemName":"Specialist treatment","depth":4,"htmlHeader":"<!-- begin field 4b1584e0-3359-4f96-b863-0c1ad578d209 --><h4>Specialist dementia treatment</h4><!-- end field 4b1584e0-3359-4f96-b863-0c1ad578d209 -->","summary":null,"htmlStringContent":"<!-- begin item fefde8fb-c772-4761-a7ac-12a75deb1403 --><!-- begin field 77e6cb96-e840-49de-9b63-787ee2a6256a --><p><strong>Specialist non-pharmacological interventions for cognitive symptoms of dementia may include:</strong></p><ul><li>Structured group cognitive stimulation programs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Winblad, 2016</a>].</li><li>Reminiscence therapy with discussion of past experiences [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Kales, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Robinson, 2015</a>].</li><li>Tools such as life histories, shared memories, and familiar objects from the past — usually in a group setting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Winblad, 2016</a>]. </li></ul><p><strong>Specialist drug treatments for cognitive symptoms of dementia should <em>always</em> be initiated by a specialist. However, treatment may be continued in primary care under a shared-care protocol. </strong><strong>They include:</strong></p><ul><li>Acetylcholinesterase (AChE) inhibitors (donepezil, galantamine, and rivastigmine) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2011</a>]:<ul><li>These drugs can be used for mild to moderate Alzheimer's disease but must only be prescribed by healthcare professionals with expertise in this area (including psychiatrists, elderly care physicians, neurologists, or other healthcare professionals [such as GPs, nurse consultants, and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease]).</li></ul></li><li>Memantine (a N-methyl-D-aspartic acid receptor antagonist) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2011</a>]:<ul><li>Memantine is an option for managing Alzheimer's disease for people with:<ul><li>Moderate Alzheimer's disease who are intolerant of, or have a contraindication to, AChE inhibitors <em>or</em></li><li>Severe Alzheimer's disease.</li></ul></li></ul></li><li>The prescription, supply, and treatment review of these drugs must be in line with the National Institute for Health and Care Excellence (NICE) guideline <em>Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2016</a>] and the treatment should only be continued when considered to be having a worthwhile effect on cognitive, global, functional, or behavioural symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li><li>Acetylcholinesterase inhibitors or memantine should not be prescribed in people with mild cognitive impairment or vascular dementia outside of clinical trials [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li><li>People started on these medications should be counselled about realistic treatment outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Galvin, 2012</a>].</li></ul><p><strong>Specialist drug treatment for behavioural and psychological symptoms of dementia (BPSD) or non-cognitive symptoms of dementia and challenging behaviour</strong></p><ul><li>No antipsychotics (except risperidone in very specific circumstances) are licensed for BPSD in the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">MHRA, 2012</a>].<ul><li>Specialists may prescribe an antipsychotic drug off-label in certain circumstances following a thorough clinical assessment and discussion (including the risks and benefits) with the carer and (if possible) the person with dementia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Hort, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2015b</a>].</li></ul></li><li>The Department of Health policy is that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Banerjee, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">DH, 2009</a>]:<ul><li>People with dementia should only be offered an anti-psychotic drug if they are severely distressed or there is an immediate risk of harm to the person or others.</li><li>GPs should review the use of antipsychotics in people with dementia and follow best practice in terms of initiation, dose minimization, and cessation of treatment.</li></ul></li><li>Antipsychotics have potentially serious adverse effects, including increased risk of stroke and mortality, Parkinsonism, and cognitive impairment. They should be used with caution, at low dose, and for the shortest time possible [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Hort, 2010</a>].</li><li>In specific situations, specialists may offer AChE inhibitors for BPSD if non-pharmacological methods and anti-psychotic drugs are inappropriate or ineffective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li></ul><!-- end field 77e6cb96-e840-49de-9b63-787ee2a6256a --><!-- end item fefde8fb-c772-4761-a7ac-12a75deb1403 -->","subChapters":[]},{"id":"36b38ebf-76be-5ac3-8ab4-72a85bc853f7","slug":"basis-for-recommendation-f17","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1d8f384d-3eb2-495a-a30c-89822173696b --><h4>Basis for recommendation</h4><!-- end field 1d8f384d-3eb2-495a-a30c-89822173696b -->","summary":null,"htmlStringContent":"<!-- begin item f1767b9e-e81c-416e-b6c7-900a7f6119ec --><!-- begin field 8a39b1c8-91f4-43e8-9a3d-a669a82d103a --><p>The recommendations on follow up of confirmed dementia in primary care are based on the National Institute of Health and Care Excellence (NICE) guideline <em>Dementia: supporting people with dementia and their carers in health and social care (CG42)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>], the European Federation of Neurological Societies (EFNS-ENS)<em> Guidelines on the diagnosis and management of disorders associated with dementia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Sorbi, 2012</a>], the Guidelines and Protocols Advisory Committee (GPAC) guideline <em>Cognitive impairment: recognition, diagnosis and management in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">GPAC, 2014</a>], the Department of Health best practice guidance <em>Nothing ventured, nothing gained: risk guidance for dementia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Department of Health, 2010</a>], the NICE Quality Standard on <em>Dementia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2010</a>], the NICE pathway on dementia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE Pathway, 2016</a>], the <em>Royal College of General Practitioners Policy Position Statement on the role of general practice in the identification and treatment of people with dementia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">RCGP, 2013</a>], the British Psychological Society briefing paper <em>Alternatives to antipsychotic medication: Psychological approaches in managing psychological and behavioural distress in people with dementia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">British Psychological Society, 2013</a>], and expert opinion in review articles on dementia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Robinson, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Villars, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Young, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Galvin, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Barrett, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Corbett, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Kales, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Robinson, 2015</a>].</p><h5><strong>Discussing the diagnosis with the person and their family/carer and providing information and support</strong></h5><ul><li>NICE recommends that healthcare professionals should make time available to discuss the diagnosis of dementia and its implications with the person with dementia and their family/carer, and provide written details of sources of information and support [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>]. </li><li>Many studies have shown that people with dementia express a preference for progressive disclosure with ongoing support [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">RCGP, 2013</a>].</li></ul><h5>Advance care planning</h5><ul><li>It is important to discuss the future in the earlier stages of the illness (while the person still has mental capacity) to allow the person and their families to express and formally record their wishes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Robinson, 2015</a>]. </li><li>NICE advises that healthcare professionals should discuss with the person with dementia, while they still has capacity, and their family/carer, the use of advance statements, advance decisions to refuse treatment, and Lasting Power of Attorney [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li></ul><h5>Monitoring physical and mental health and functional ability</h5><ul><li>The NICE dementia guideline recommends that healthcare professionals should aim to promote and maintain independence of people with dementia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>]. </li><li>Referral to appropriate services such as occupational therapy can benefit the person's daily functioning and reduce the need for informal care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Hort, 2010</a>].</li><li>Expert opinion in review articles on dementia is that:<ul><li>Sub-optimally managed co-morbidities can exacerbate symptoms of dementia — appropriate treatment can improve functional ability [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Villars, 2010</a>].</li><li>Delirium can cause an abrupt deterioration in cognitive function — cognitive impairment is a risk factor for delirium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Young, 2011</a>].</li></ul></li></ul><h5>Monitoring response to dementia treatments</h5><ul><li>This recommendation is based on expert opinion in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li></ul><h5>Behavioural and psychological symptoms of dementia (BPSD)</h5><ul><li>People with BPSD should be assessed at the earliest opportunity to identify factors that may have precipitated or exacerbated such behaviour [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li><li>Current guidance recommends non-pharmacological approaches first line in managing BPSD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Banerjee, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">DH, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">British Psychological Society, 2013</a>].<ul><li>Many behaviours identified as challenging are due to pain, distress, disorientation and misperception, and underlying causes should be addressed and managed if possible before considering pharmacological measures that sedate or tranquillize [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">British Psychological Society, 2013</a>].<ul><li>Pain is a common precipitant or exacerbating factor in BPSD. A randomized controlled trial (n = 352) found a 17% improvement in agitation following stepped analgesic treatment, similar to the benefit found following antipsychotic use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Corbett, 2012</a>].</li><li>Non-pharmacological treatment of BPSD should be tailored to the person's preferences, skills and abilities. The response should be monitored, and the care plan adapted accordingly. Approaches recommended by NICE include aromatherapy, multisensory stimulation, therapeutic use of music and/or dancing, animal-assisted therapy, and massage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li></ul></li></ul></li><li>Pharmacological interventions for BPSD should only be offered if the person is severely distressed or there is an immediate risk of harm to the person or others.<ul><li>No antipsychotic (except risperidone in very specific circumstances) is licensed for use in the UK for the behavioural and psychological symptoms of dementia. However some specialists may prescribe short-term antipsychotics off label in certain circumstances [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">MHRA, 2012</a>].</li><li>The potential harms of antipsychotic medication (such as increased cerebrovascular events and mortality) outweigh the benefits [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Corbett, 2014</a>].<ul><li>In one retrospective case-control study (n = 90,786) compared with respective matched non-users, people with dementia receiving haloperidol had an increased mortality risk of 3.8% (95% CI, 1.0%–6.6%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Maust, 2015</a>].</li><li>NICE recommends that healthcare professionals using pharmacological treatment (specifically benzodiazepines and antipsychotics) as a last resort in the management of violence, aggression, and extreme agitation in people with dementia should be trained in the correct use of drugs for behavioural control [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>]. CKS therefore recommends that specialist advice should be sought before these drugs are commenced in primary care in this situation.</li></ul></li></ul></li></ul><h5>Carer assessment and support</h5><ul><li>Stress, depression, and ill health are more common in carers of people with dementia than carers of people with other conditions. Monitoring health and wellbeing and providing education and support to carers can decrease psychiatric symptoms and delay institutionalization of the person with dementia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Hort, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Robinson, 2015</a>].</li><li>Referral of carers to multicomponent educational programmes and psychological interventions (especially cognitive behaviour therapy) has been shown to produce a small but consistent benefit to carers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">Cameron, 2011</a>].</li><li>NICE recommends that health and social care managers should ensure that carers of people with dementia have access to respite or short-break services, such as, day care, day- and night-sitting, adult placement and short-term and/or overnight residential care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>].</li></ul><h5>When to seek advice/refer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>]</h5><ul><li>NICE recommend that treatment with antidepressant medication in people with dementia should only be initiated following assessment by a specialist.</li><li>Non-pharmacological interventions for depression and anxiety in dementia include cognitive behaviour therapy, reminiscence therapy, multisensory stimulation, animal-assisted therapy and exercise.</li></ul><!-- end field 8a39b1c8-91f4-43e8-9a3d-a669a82d103a --><!-- end item f1767b9e-e81c-416e-b6c7-900a7f6119ec -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}